B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer

NCT03953833 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

BIOLOGICAL: Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.

Sponsor

Shanghai Pharmaceuticals Holding Co., Ltd